Asia Pacific Pharmaceutical CDMO for Formulations Market Size is USD 12.27 Billion by 2026

Asia Pacific Pharmaceutical CDMO for Formulations Market (By Dosage Form: Oral Solids, Oral Liquids, Injectables, Topicals, Inhalation Products, Transdermal And Patches, Others; By Therapeutic Area: Oncology, Cardiology, Central Nervous System, Gastroenterology, Infectious Diseases, Endocrinology (Diabetes, Hormonal Therapy); By End User: Pharmaceutical Companies, Biopharmaceutical Companies, Others) Industry Size, Share, Growth, Trends 2025 to 2035

Report Code : 606 | Published : 11 May 2026 | Delivery : Immediate | Format : Excel | Author : Aditi Shivarkar, Aman Singh

Revenue,

USD 11.24 Bn

Forecast Year,

USD 27.10 Bn

CAGR, 2026 - 2035

9.20%

Report Coverage

Asia Pacific

Download Databook

The Asia Pacific pharmaceutical CDMO for formulations market size was estimated at USD 11.24 billion in 2025 and is expanding at a CAGR of 9.20% from 2026 to 2035. Due to low manufacturing costs, skilled labor, and increasing pharmaceutical outsourcing, countries like India and China are becoming key formulation manufacturing hubs, rising demand for generics, biologics, and complex duct formulations is also supporting market growth.

Asia Pacific Pharmaceutical CDMO for Formulations Market Statical Scope

Reports Attributes	Statistics
Market Size in 2025	USD 11.24 Billion
Market Size in 2026	USD 12.27 Billion
Market Size by 2035	USD 27.10 Billion
CAGR 2026 to 2035	9.20%
Base Year	2025
Forecast Period	2026 to 2035

It is increasing focus on advanced formations, sterile injectables, and personalized medicine , offers cost- effective production with improving regulatory standards, attracting global pharmaceutical companies.

Technologies such as automation, continuous manufacturing, AI- based process optimization, and single-use systems are improving production efficiency and quality, making Asia Pacific a strong and competitive CDMO market.

Segments	Shares (%)
Oral Solids	31%
Oral Liquids	11%
Injectables	29%
Topicals	10%
Inhalation Products	8%
Transdermal and Patches	6%
Others	5%

Oral Solids - The oral solids segment dominated the market with a share of 31% in 2025, due to their cost- effectiveness, easy, large-scale manufacturing, long shelf-life, patient convenience, and widespread use in treating chronic diseases like diabetes and hypertension.
Oral Liquids - The oral liquids are rapidly growing with a market share of 11%, due to paediatric preference, easy administration, flexible dosing, and choosing using cough, antibiotic and vitamin syrups.
Injectables - The injectables segment held a 29% market share in 2025 and is expected to grow at a steady rate, due to rising biologics demand, faster therapeutic action, hospital use, and increasing production of sterile drug products.

Segments	Shares (%)
Oncology	26%
Cardiology	19%
Central Nervous System	17%
Gastroenterology	12%
Infectious Diseases	15%
Endocrinology (Diabetes, Hormonal Therapy)	11%

Oncology - The oncology segment dominated the market with a share of 26% in 2025, due to increasing cancer prevalence, strong demand for targeted therapies, biologics, and continuous investment in advanced anti-cancer drug development and manufacturing.
Cardiology - The cardiology segment held a 19% market share in 2025 and is expected to grow at a steady rate, due to rising burden of cardiovascular diseases, increasing lifestyle related risk factors, and growing demand for long-term, cost- effective heart disease treatments and preventive therapies.
Central Nervous System - The central nervous system are rapidly growing with a market share of 17%, due to increasing cases of neurological disorders, depression and Alzheimer's disease, rising awareness, improved, diagnosis and growing demand for long term therapies also drive outsourcing of complex formulation development and manufacturing.

Segments	Shares (%)
Pharmaceutical Companies	52%
Biopharmaceutical Companies	38%
Others	10%

Pharmaceutical Companies - The pharmaceutical companies segment dominated the market with a share of 52% in 2025, due to increasing outsourcing, cost-efficient manufacturing, faster drug development, n and growing demand for large scale formulation protection services.
Biopharmaceutical Companies - The biopharmaceutical companies segment held a 38% market share in 2025 and is expected to grow at a steady rate, due to increasing focus on biologics, vaccines and biosimilar, complex manufacturing needs, and strong outsourcing trends drive companies to partner with CDMOs for efficient, scalable, and compliant production.
Others - The others are rapidly growing with a market share of 10%, due to growing participation from academic institutes, contract research organisations, and small startups, these groups increasingly outsource formulation work for cost efficiency, faster development, add access to advanced manufacturing capabilities

Top Companies in the Asia Pacific Pharmaceutical CDMO for Formulations Market

Lonza
Thermo Fisher Scientific, Inc.
Recipharm AB
Laboratory Corporation of America Holdings (LabCorp)
Catalent, Inc.
WuXi AppTec, Inc.
Piramal Pharma Solutions
Siegfried Holding AG
CordenPharma International
Cambrex Corporation
Bushu Pharmaceuticals Ltd.
Nipro Corporation
EuroAPI
Hovione
Curia

Segments Covered in the Report

By Dosage Form

Oral Solids
Oral Liquids
Injectables
Topicals
Inhalation Products
Transdermal And Patches
Others

By Therapeutic Area

Oncology
Cardiology
Central Nervous System
Gastroenterology
Infectious Diseases
Endocrinology (Diabetes, Hormonal Therapy)

By End User

Pharmaceutical Companies
Biopharmaceutical Companies
Others

List of Tables & Figures

List of Tables

Table 1: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Dosage Form, 2025-2035 (USD Billion)
Table 2: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Oral Solids, 2025-2035 (USD Billion)
Table 3: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Oral Liquids, 2025-2035 (USD Billion)
Table 4: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Injectables, 2025-2035 (USD Billion)
Table 5: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Topicals, 2025-2035 (USD Billion)
Table 6: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Inhalation Products, 2025-2035 (USD Billion)
Table 7: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Transdermal & Patches, 2025-2035 (USD Billion)
Table 8: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Others (Dosage Form), 2025-2035 (USD Billion)
Table 9: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Therapeutic Area, 2025-2035 (USD Billion)
Table 10: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Oncology, 2025-2035 (USD Billion)
Table 11: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Cardiology, 2025-2035 (USD Billion)
Table 12: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Central Nervous System, 2025-2035 (USD Billion)
Table 13: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Gastroenterology, 2025-2035 (USD Billion)
Table 14: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Infectious Diseases, 2025-2035 (USD Billion)
Table 15: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Endocrinology (Diabetes, Hormonal Therapy), 2025-2035 (USD Billion)Table 16:
Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by End User, 2025-2035 (USD Billion)
Table 17: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Pharmaceutical Companies, 2025-2035 (USD Billion)
Table 18: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Biopharmaceutical Companies, 2025-2035 (USD Billion)
Table 19: Asia Pacific Pharmaceutical CDMO for Formulations Market Size, by Others (End User), 2025-2035 (USD Billion)
Table 20: China Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 21: Japan Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 22: South Korea Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 23: Southeast Asia Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 24: India Pharmaceutical CDMO for Formulations Market Size, 2025-2035 (USD Billion)
Table 25: Asia Pacific Pharmaceutical CDMO for Formulations Market Share, by Dosage Form, 2025 (%)
Table 26: Asia Pacific Pharmaceutical CDMO for Formulations Market Share, by Therapeutic Area, 2025 (%)
Table 27: Asia Pacific Pharmaceutical CDMO for Formulations Market Share, by End User, 2025 (%)

List of Figures

Figure 1: Asia Pacific Pharmaceutical CDMO for Formulations Market Share, by Dosage Form, 2025 (%)
Figure 2: Asia Pacific Pharmaceutical CDMO for Formulations Market Share, by Therapeutic Area, 2025 (%)
Figure 3: Asia Pacific Pharmaceutical CDMO for Formulations Market Share, by End User, 2025 (%)
Figure 4: Asia Pacific Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 5: Asia Pacific Oral Solids Market Forecast, 2025-2035 (USD Billion)
Figure 6: Asia Pacific Oral Liquids Market Forecast, 2025-2035 (USD Billion)
Figure 7: Asia Pacific Injectables Market Forecast, 2025-2035 (USD Billion)
Figure 8: Asia Pacific Topicals Market Forecast, 2025-2035 (USD Billion)
Figure 9: Asia Pacific Inhalation Products Market Forecast, 2025-2035 (USD Billion)
Figure 10: Asia Pacific Transdermal & Patches Market Forecast, 2025-2035 (USD Billion)
Figure 11: Asia Pacific Oncology Market Forecast, 2025-2035 (USD Billion)
Figure 12: Asia Pacific Cardiology Market Forecast, 2025-2035 (USD Billion)
Figure 13: Asia Pacific Central Nervous System Market Forecast, 2025-2035 (USD Billion)
Figure 14: Asia Pacific Gastroenterology Market Forecast, 2025-2035 (USD Billion)
Figure 15: Asia Pacific Infectious Diseases Market Forecast, 2025-2035 (USD Billion)
Figure 16: Asia Pacific Endocrinology Market Forecast, 2025-2035 (USD Billion)
Figure 17: Asia Pacific Pharmaceutical Companies Segment Forecast, 2025-2035 (USD Billion)
Figure 18: Asia Pacific Biopharmaceutical Companies Segment Forecast, 2025-2035 (USD Billion)
Figure 19: China Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 20: Japan Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 21: South Korea Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 22: Southeast Asia Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)
Figure 23: India Pharmaceutical CDMO for Formulations Market Forecast, 2025-2035 (USD Billion)

Research Methodology

Related Databooks

March 2026